Gilead Has Full HIV Policy Agenda For 2019: Part D Challenge; Prophylaxis Increase
Gilead faces two-pronged policy challenge in its core HIV business: its Part D product line could lose protections, but prophylactic prescriptions could dramatically expand under the Trump Administration's plan to eliminate HIV transmission.
You may also be interested in...
US Initiative To End HIV Epidemic Will Boost PrEP Access
'Number of different initiatives' coming in next several months to make drugs more affordable, including for PrEP prophylaxis, HHS Assistant Secretary for Health Giroir says. Multi-agency approach is key strategy.
Carrots Or Sticks: Which Way Might Medicare's Protected Classes Reforms Go?
UnitedHealthcare program for commercial members offers some implications. MyScripRewards encourages less costly HIV treatments using financial rewards, underscoring insurers’ tendency to favor carrots over sticks when it comes to coverage policies for such drugs.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.